Perkins Capital Management’s Perspective Therapeutics CATX Stock Holding History

Perkins Capital Management’s Portfolio CATX Stock Details CATX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$62.1K	Buy	+18,200	New	+$68.8K	0.05%	75
2024 Q1	–	Sell	-70,000	Closed	-$281K	–	92
2023 Q4	$281K	Sell	70,000 -197,164	-74%	-$555K	0.24%	74
2023 Q3	$731K	Sell	267,164 -300	-0.1%	-$1.4K	0.72%	44
2023 Q2	$1.79M	Sell	267,464 -7,500	-3%	-$45.5K	1.56%	22
2023 Q1	$1.75M	Sell	274,964 -2,300	-0.8%	-$9.39K	1.65%	20
2022 Q4	$685K	Sell	277,264 -7,800	-3%	-$25.7K	0.72%	42
2022 Q3	$655K	Sell	285,064 -6,386	-2%	-$21.8K	0.73%	44
2022 Q2	$901K	Buy	291,450 +11,600	+4%	+$35.4K	0.93%	39
2022 Q1	$1.02M	Sell	279,850 -250	-0.1%	-$912	0.83%	45
2021 Q4	$1.09M	Buy	280,100 +124,800	+80%	+$666K	0.73%	50
2021 Q3	$980K	Sell	155,300 -10,100	-6%	-$68.8K	0.61%	48
2021 Q2	$1.32M	Buy	165,400 +25,500	+18%	+$223K	0.75%	43
2021 Q1	$1.52M	Buy	139,900 +89,900	+180%	+$1.36M	0.88%	40
2020 Q4	$225K	Buy	+50,000	New	+$221K	0.15%	85

Other funds holding CATX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

SSC

Spruce Street Capital New York $510M AUM

Perkins Capital Management's CATX Position: Q2 2026 in Review

Perkins Capital Management opened a new position in Perspective Therapeutics (CATX) in Q2 2026: 18,200 shares worth $62.1K. The stake represents 0.05% of the portfolio and ranks #75 among its holdings. This is a return to the name: Perkins Capital Management previously reported a position in CATX as recently as Q4 2023.

Perkins Capital Management first reported a position in CATX in Q4 2020 and has held it in 14 quarters since. The position peaked at $1.79M in Q2 2023. 132 funds tracked by Wall St. Rank hold CATX as of Q2 2026.

Perkins Capital Management held 18,200 shares of Perspective Therapeutics worth $62.1K as of Q2 2026.
Perspective Therapeutics was a new Perkins Capital Management position in Q2 2026.
Perspective Therapeutics made up 0.05% of Perkins Capital Management's portfolio in Q2 2026, its #75 holding.
Perkins Capital Management first reported a position in Perspective Therapeutics in Q4 2020 and has held it in 14 quarters since.
Perkins Capital Management's Perspective Therapeutics position peaked at $1.79M in Q2 2023.
132 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q2 2026.

Based on Perkins Capital Management's 13F filing for Q2 2026, filed 24 Jul 2026.